Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 183

1.

Formin Proteins FHOD1 and INF2 in Triple-Negative Breast Cancer: Association With Basal Markers and Functional Activities.

Heuser VD, Mansuri N, Mogg J, Kurki S, Repo H, Kronqvist P, Carpén O, Gardberg M.

Breast Cancer (Auckl). 2018 Aug 24;12:1178223418792247. doi: 10.1177/1178223418792247. eCollection 2018.

2.

EGFR gene copy number decreases during anti-EGFR antibody therapy in colorectal cancer.

Birkman EM, Avoranta T, Ålgars A, Korkeila E, Lintunen M, Lahtinen L, Kuopio T, Ristamäki R, Carpén O, Sundström J.

Hum Pathol. 2018 Aug 7. pii: S0046-8177(18)30296-X. doi: 10.1016/j.humpath.2018.07.028. [Epub ahead of print]

3.

Real-world features associated with cancer-related venous thromboembolic events.

Peippo MH, Kurki S, Lassila R, Carpén OM.

ESMO Open. 2018 Jul 23;3(5):e000363. doi: 10.1136/esmoopen-2018-000363. eCollection 2018.

4.

Identifying differentially methylated sites in samples with varying tumor purity.

Häkkinen A, Alkodsi A, Facciotto C, Zhang K, Kaipio K, Leppä S, Carpén O, Grénman S, Hynninen J, Hietanen S, Lehtonen R, Hautaniemi S.

Bioinformatics. 2018 Sep 15;34(18):3078-3085. doi: 10.1093/bioinformatics/bty310.

PMID:
29912358
5.

A Functional Homologous Recombination Assay Predicts Primary Chemotherapy Response and Long-Term Survival in Ovarian Cancer Patients.

Tumiati M, Hietanen S, Hynninen J, Pietilä E, Färkkilä A, Kaipio K, Roering P, Huhtinen K, Alkodsi A, Li Y, Lehtonen R, Erkan EP, Tuominen MM, Lehti K, Hautaniemi SK, Vähärautio A, Grénman S, Carpén O, Kauppi L.

Clin Cancer Res. 2018 Sep 15;24(18):4482-4493. doi: 10.1158/1078-0432.CCR-17-3770. Epub 2018 Jun 1.

PMID:
29858219
6.

Mathematical Modeling Predicts Response to Chemotherapy and Drug Combinations in Ovarian Cancer.

Kozłowska E, Färkkilä A, Vallius T, Carpén O, Kemppainen J, Grénman S, Lehtonen R, Hynninen J, Hietanen S, Hautaniemi S.

Cancer Res. 2018 Jul 15;78(14):4036-4044. doi: 10.1158/0008-5472.CAN-17-3746. Epub 2018 May 16.

PMID:
29769198
7.

Prognostic and diagnostic value of REG4 serum and tissue expression in pancreatic ductal adenocarcinoma.

Saukkonen K, Hagström J, Mustonen H, Lehtinen L, Carpen O, Andersson LC, Seppänen H, Haglund C.

Tumour Biol. 2018 Mar;40(3):1010428318761494. doi: 10.1177/1010428318761494.

PMID:
29542402
8.

Combined ASRGL1 and p53 immunohistochemistry as an independent predictor of survival in endometrioid endometrial carcinoma.

Huvila J, Laajala TD, Edqvist PH, Mardinoglu A, Talve L, Pontén F, Grénman S, Carpén O, Aittokallio T, Auranen A.

Gynecol Oncol. 2018 Apr;149(1):173-180. doi: 10.1016/j.ygyno.2018.02.016. Epub 2018 Mar 2.

PMID:
29486992
9.

The Expression of HSD17B12 Is Associated with COX-2 Expression and Is Increased in High-Grade Epithelial Ovarian Cancer.

Kemiläinen H, Huhtinen K, Auranen A, Carpén O, Strauss L, Poutanen M.

Oncology. 2018;94(4):233-242. doi: 10.1159/000485624. Epub 2018 Jan 12.

PMID:
29324448
10.

Trends in presentation, treatment and survival of 1777 patients with colorectal cancer over a decade: a Biobank study.

Heervä E, Carpelan A, Kurki S, Sundström J, Huhtinen H, Rantala A, Ålgars A, Ristamäki R, Carpén O, Minn H.

Acta Oncol. 2018 Jun;57(6):735-742. doi: 10.1080/0284186X.2017.1420230. Epub 2017 Dec 23.

PMID:
29275667
11.
12.

Integrated genome analysis of uterine leiomyosarcoma to identify novel driver genes and targetable pathways.

Cuppens T, Moisse M, Depreeuw J, Annibali D, Colas E, Gil-Moreno A, Huvila J, Carpén O, Zikán M, Matias-Guiu X, Moerman P, Croce S, Lambrechts D, Amant F.

Int J Cancer. 2018 Mar 15;142(6):1230-1243. doi: 10.1002/ijc.31129. Epub 2017 Nov 7.

PMID:
29063609
13.

Gastric cancer: immunohistochemical classification of molecular subtypes and their association with clinicopathological characteristics.

Birkman EM, Mansuri N, Kurki S, Ålgars A, Lintunen M, Ristamäki R, Sundström J, Carpén O.

Virchows Arch. 2018 Mar;472(3):369-382. doi: 10.1007/s00428-017-2240-x. Epub 2017 Oct 19.

14.

Ezrin expression combined with MSI status in prognostication of stage II colorectal cancer.

Slik K, Kurki S, Korpela T, Carpén O, Korkeila E, Sundström J.

PLoS One. 2017 Sep 27;12(9):e0185436. doi: 10.1371/journal.pone.0185436. eCollection 2017.

15.

DNA methylation and Transcriptome Changes Associated with Cisplatin Resistance in Ovarian Cancer.

Lund RJ, Huhtinen K, Salmi J, Rantala J, Nguyen EV, Moulder R, Goodlett DR, Lahesmaa R, Carpén O.

Sci Rep. 2017 May 4;7(1):1469. doi: 10.1038/s41598-017-01624-4.

16.

Hyper-phosphorylation of Sequestosome-1 Distinguishes Resistance to Cisplatin in Patient Derived High Grade Serous Ovarian Cancer Cells.

Nguyen EV, Huhtinen K, Goo YA, Kaipio K, Andersson N, Rantanen V, Hynninen J, Lahesmaa R, Carpen O, Goodlett DR.

Mol Cell Proteomics. 2017 Jul;16(7):1377-1392. doi: 10.1074/mcp.M116.058321. Epub 2017 Apr 28.

17.

PLA2G7 associates with hormone receptor negativity in clinical breast cancer samples and regulates epithelial-mesenchymal transition in cultured breast cancer cells.

Lehtinen L, Vainio P, Wikman H, Huhtala H, Mueller V, Kallioniemi A, Pantel K, Kronqvist P, Kallioniemi O, Carpèn O, Iljin K.

J Pathol Clin Res. 2017 Apr 4;3(2):123-138. doi: 10.1002/cjp2.69. eCollection 2017 Apr.

18.

A Selective Biomarker Panel Increases the Reproducibility and the Accuracy in Endometrial Biopsy Diagnosis.

Nastic D, Shanwell E, Wallin KL, Valla M, Måsbäck A, Mateoiu C, Lidang M, Liakka A, Lappi-Blanco E, Grove A, Davidson B, Carpen O, Bertelsen BI, Bak J, Abusland AB, Selling J, Carlson JW.

Int J Gynecol Pathol. 2017 Jul;36(4):339-347. doi: 10.1097/PGP.0000000000000334.

PMID:
28244894
19.

Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas-an ENITEC Group Initiative.

Cuppens T, Annibali D, Coosemans A, Trovik J, Ter Haar N, Colas E, Garcia-Jimenez A, Van de Vijver K, Kruitwagen RP, Brinkhuis M, Zikan M, Dundr P, Huvila J, Carpén O, Haybaeck J, Moinfar F, Salvesen HB, Stukan M, Mestdagh C, Zweemer RP, Massuger LF, Mallmann MR, Wardelmann E, Mints M, Verbist G, Thomas D, Gommé E, Hermans E, Moerman P, Bosse T, Amant F.

Clin Cancer Res. 2017 Mar 1;23(5):1274-1285. doi: 10.1158/1078-0432.CCR-16-2149.

20.

Breast cancer in neurofibromatosis type 1: overrepresentation of unfavourable prognostic factors.

Uusitalo E, Kallionpää RA, Kurki S, Rantanen M, Pitkäniemi J, Kronqvist P, Härkönen P, Huovinen R, Carpen O, Pöyhönen M, Peltonen S, Peltonen J.

Br J Cancer. 2017 Jan 17;116(2):211-217. doi: 10.1038/bjc.2016.403. Epub 2016 Dec 8.

21.

FHOD1 formin is upregulated in melanomas and modifies proliferation and tumor growth.

Peippo M, Gardberg M, Lamminen T, Kaipio K, Carpén O, Heuser VD.

Exp Cell Res. 2017 Jan 1;350(1):267-278. doi: 10.1016/j.yexcr.2016.12.004. Epub 2016 Dec 2.

22.

EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.

Ålgars A, Sundström J, Lintunen M, Jokilehto T, Kytölä S, Kaare M, Vainionpää R, Orpana A, Österlund P, Ristimäki A, Carpen O, Ristamäki R.

Int J Cancer. 2017 Feb 15;140(4):922-929. doi: 10.1002/ijc.30507. Epub 2016 Nov 23.

23.

A Nanoparticle-Lectin Immunoassay Improves Discrimination of Serum CA125 from Malignant and Benign Sources.

Gidwani K, Huhtinen K, Kekki H, van Vliet S, Hynninen J, Koivuviita N, Perheentupa A, Poutanen M, Auranen A, Grenman S, Lamminmäki U, Carpen O, van Kooyk Y, Pettersson K.

Clin Chem. 2016 Oct;62(10):1390-400. doi: 10.1373/clinchem.2016.257691. Epub 2016 Aug 18.

24.

FMNL2/FMNL3 formins are linked with oncogenic pathways and predict melanoma outcome.

Gardberg M, Heuser VD, Koskivuo I, Koivisto M, Carpén O.

J Pathol Clin Res. 2016 Jan 21;2(1):41-52. doi: 10.1002/cjp2.34. eCollection 2016 Jan.

25.

EGFR gene amplification is relatively common and associates with outcome in intestinal adenocarcinoma of the stomach, gastro-oesophageal junction and distal oesophagus.

Birkman EM, Ålgars A, Lintunen M, Ristamäki R, Sundström J, Carpén O.

BMC Cancer. 2016 Jul 7;16:406. doi: 10.1186/s12885-016-2456-1.

26.

REG4 Is Highly Expressed in Mucinous Ovarian Cancer: A Potential Novel Serum Biomarker.

Lehtinen L, Vesterkvist P, Roering P, Korpela T, Hattara L, Kaipio K, Mpindi JP, Hynninen J, Auranen A, Davidson B, Haglund C, Iljin K, Grenman S, Siitari H, Carpen O.

PLoS One. 2016 Mar 16;11(3):e0151590. doi: 10.1371/journal.pone.0151590. eCollection 2016.

27.

Novel Mad2-targeting miR-493-3p controls mitotic fidelity and cancer cells' sensitivity to paclitaxel.

Tambe M, Pruikkonen S, Mäki-Jouppila J, Chen P, Elgaaen BV, Straume AH, Huhtinen K, Cárpen O, Lønning PE, Davidson B, Hautaniemi S, Kallio MJ.

Oncotarget. 2016 Mar 15;7(11):12267-85. doi: 10.18632/oncotarget.7860.

28.

18F-FDG-PET/CT can identify histopathological non-responders to platinum-based neoadjuvant chemotherapy in advanced epithelial ovarian cancer.

Vallius T, Peter A, Auranen A, Carpén O, Kemppainen J, Matomäki J, Oksa S, Roering P, Seppänen M, Grénman S, Hynninen J.

Gynecol Oncol. 2016 Jan;140(1):29-35. doi: 10.1016/j.ygyno.2015.10.018. Epub 2015 Oct 26.

PMID:
26515076
29.

Identification of Prognostic Groups in High-Grade Serous Ovarian Cancer Treated with Platinum-Taxane Chemotherapy.

Chen P, Huhtinen K, Kaipio K, Mikkonen P, Aittomäki V, Lindell R, Hynninen J, Auranen A, Grénman S, Lehtonen R, Carpén O, Hautaniemi S.

Cancer Res. 2015 Aug 1;75(15):2987-98. doi: 10.1158/0008-5472.CAN-14-3242. Epub 2015 Jun 29.

30.

Loss of ASRGL1 expression is an independent biomarker for disease-specific survival in endometrioid endometrial carcinoma.

Edqvist PH, Huvila J, Forsström B, Talve L, Carpén O, Salvesen HB, Krakstad C, Grénman S, Johannesson H, Ljungqvist O, Uhlén M, Pontén F, Auranen A.

Gynecol Oncol. 2015 Jun;137(3):529-37. doi: 10.1016/j.ygyno.2015.03.055. Epub 2015 Apr 7.

PMID:
25858696
31.

CIP2A is an Oct4 target gene involved in head and neck squamous cell cancer oncogenicity and radioresistance.

Ventelä S, Sittig E, Mannermaa L, Mäkelä JA, Kulmala J, Löyttyniemi E, Strauss L, Cárpen O, Toppari J, Grénman R, Westermarck J.

Oncotarget. 2015 Jan 1;6(1):144-58.

32.

N-glycomic profiling as a tool to separate rectal adenomas from carcinomas.

Kaprio T, Satomaa T, Heiskanen A, Hokke CH, Deelder AM, Mustonen H, Hagström J, Carpen O, Saarinen J, Haglund C.

Mol Cell Proteomics. 2015 Feb;14(2):277-88. doi: 10.1074/mcp.M114.041632. Epub 2014 Dec 1.

33.

Serum HE4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer.

Vallius T, Hynninen J, Auranen A, Carpén O, Matomäki J, Oksa S, Virtanen J, Grénman S.

Tumour Biol. 2014 Dec;35(12):12389-95. doi: 10.1007/s13277-014-2553-1. Epub 2014 Sep 5.

PMID:
25190018
34.

Actin-associated protein palladin promotes tumor cell invasion by linking extracellular matrix degradation to cell cytoskeleton.

von Nandelstadh P, Gucciardo E, Lohi J, Li R, Sugiyama N, Carpen O, Lehti K.

Mol Biol Cell. 2014 Sep 1;25(17):2556-70. doi: 10.1091/mbc.E13-11-0667. Epub 2014 Jul 2.

35.

Heterogeneous EGFR gene copy number increase is common in colorectal cancer and defines response to anti-EGFR therapy.

Ålgars A, Avoranta T, Österlund P, Lintunen M, Sundström J, Jokilehto T, Ristimäki A, Ristamäki R, Carpén O.

PLoS One. 2014 Jun 18;9(6):e99590. doi: 10.1371/journal.pone.0099590. eCollection 2014.

36.

Tensin-4-Dependent MET Stabilization Is Essential for Survival and Proliferation in Carcinoma Cells.

Muharram G, Sahgal P, Korpela T, De Franceschi N, Kaukonen R, Clark K, Tulasne D, Carpén O, Ivaska J.

Dev Cell. 2014 Jun 9;29(5):629-630. doi: 10.1016/j.devcel.2014.05.018. Epub 2014 Jun 9. No abstract available.

37.

Tensin-4-dependent MET stabilization is essential for survival and proliferation in carcinoma cells.

Muharram G, Sahgal P, Korpela T, De Franceschi N, Kaukonen R, Clark K, Tulasne D, Carpén O, Ivaska J.

Dev Cell. 2014 May 27;29(4):421-36. doi: 10.1016/j.devcel.2014.03.024. Epub 2014 May 8. Erratum in: Dev Cell. 2014 Jun 9:29(5):629-30.

38.

Characterization of Leukocyte Formin FMNL1 Expression in Human Tissues.

Gardberg M, Heuser VD, Iljin K, Kampf C, Uhlen M, Carpén O.

J Histochem Cytochem. 2014 Jun;62(6):460-470. Epub 2014 Apr 3.

39.

Palladin promotes assembly of non-contractile dorsal stress fibers through VASP recruitment.

Gateva G, Tojkander S, Koho S, Carpen O, Lappalainen P.

J Cell Sci. 2014 May 1;127(Pt 9):1887-98. doi: 10.1242/jcs.135780. Epub 2014 Feb 4.

40.

Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry.

Köbel M, Bak J, Bertelsen BI, Carpen O, Grove A, Hansen ES, Levin Jakobsen AM, Lidang M, Måsbäck A, Tolf A, Gilks CB, Carlson JW.

Histopathology. 2014 Jun;64(7):1004-13. doi: 10.1111/his.12349. Epub 2014 Mar 7.

PMID:
24329781
41.

FHOD1, a formin upregulated in epithelial-mesenchymal transition, participates in cancer cell migration and invasion.

Gardberg M, Kaipio K, Lehtinen L, Mikkonen P, Heuser VD, Talvinen K, Iljin K, Kampf C, Uhlen M, Grénman R, Koivisto M, Carpén O.

PLoS One. 2013 Sep 26;8(9):e74923. doi: 10.1371/journal.pone.0074923. eCollection 2013.

42.

A prospective comparison of integrated FDG-PET/contrast-enhanced CT and contrast-enhanced CT for pretreatment imaging of advanced epithelial ovarian cancer.

Hynninen J, Kemppainen J, Lavonius M, Virtanen J, Matomäki J, Oksa S, Carpén O, Grénman S, Seppänen M, Auranen A.

Gynecol Oncol. 2013 Nov;131(2):389-94. doi: 10.1016/j.ygyno.2013.08.023. Epub 2013 Aug 29.

PMID:
23994535
43.

Eukaryotic translation initiation factor 4E (eIF4E) expression is associated with breast cancer tumor phenotype and predicts survival after anthracycline chemotherapy treatment.

Heikkinen T, Korpela T, Fagerholm R, Khan S, Aittomäki K, Heikkilä P, Blomqvist C, Carpén O, Nevanlinna H.

Breast Cancer Res Treat. 2013 Aug;141(1):79-88. doi: 10.1007/s10549-013-2671-2. Epub 2013 Aug 24.

PMID:
23974830
44.

Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma.

Huvila J, Talve L, Carpén O, Edqvist PH, Pontén F, Grénman S, Auranen A.

Gynecol Oncol. 2013 Sep;130(3):463-9. doi: 10.1016/j.ygyno.2013.06.015. Epub 2013 Jun 15.

PMID:
23777659
45.

[Pathology at the interface of basic and clinical research].

Carpén O, Kosma VM.

Duodecim. 2013;129(10):1080-7. Review. Finnish.

PMID:
23767138
46.

ALDH1 expression indicates chemotherapy resistance and poor outcome in node-negative rectal cancer.

Avoranta ST, Korkeila EA, Ristamäki RH, Syrjänen KJ, Carpén OM, Pyrhönen SO, Sundström JT.

Hum Pathol. 2013 Jun;44(6):966-74. doi: 10.1016/j.humpath.2012.10.003. Epub 2013 Jan 17.

PMID:
23332924
47.

Is perioperative visual estimation of intra-abdominal tumor spread reliable in ovarian cancer surgery after neoadjuvant chemotherapy?

Hynninen J, Lavonius M, Oksa S, Grénman S, Carpén O, Auranen A.

Gynecol Oncol. 2013 Feb;128(2):229-32. doi: 10.1016/j.ygyno.2012.11.007. Epub 2012 Nov 9.

PMID:
23142076
48.

Altered expression of ezrin, E-Cadherin and β-Catenin in cervical neoplasia.

Auvinen E, Carpen O, Korpela T, Ronty M, Vaheri A, Tarkkanen J.

Neoplasma. 2013;60(1):56-61. doi: 10.4149/neo_2013_008.

PMID:
23067217
49.

MMP-13 regulates growth of wound granulation tissue and modulates gene expression signatures involved in inflammation, proteolysis, and cell viability.

Toriseva M, Laato M, Carpén O, Ruohonen ST, Savontaus E, Inada M, Krane SM, Kähäri VM.

PLoS One. 2012;7(8):e42596. doi: 10.1371/journal.pone.0042596. Epub 2012 Aug 7.

50.

Distribution of prolyl oligopeptidase in human peripheral tissues and in ovarian and colorectal tumors.

Myöhänen TT, Pyykkö E, Männistö PT, Carpen O.

J Histochem Cytochem. 2012 Sep;60(9):706-15. doi: 10.1369/0022155412453051. Epub 2012 Jun 26.

Supplemental Content

Loading ...
Support Center